A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2016
At a glance
- Drugs KX 01 (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Athenex
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 28 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.